Michael Schotsaert

7 Hills Pharma, LLC

NIH Rank #4729
  • R01 Holder
  • Multi-Institutional
  • Early Career
  • Diverse Portfolio

NIH Funding · FY2024

Total Funding
$2.1M
Fiscal year 2024
Grants Awarded
4
Active NIH grants
National Rank
#4,729
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $2.1M across 4 grants · National rank #4729.

Top grants by award amount

Michael Schotsaert's NIH grant portfolio, ranked by award amount.

  • 5R44AI176894-02R44
    7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination
    $953.5K
    award amount
  • 5R01AI160706-03R01
    Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy
    $725.8K
    award amount
  • 1R21AI180874-01R21
    Impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infection
    $264.3K
    award amount
  • 5R21AI176069-02R21
    Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
    $204.8K
    award amount

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    7 Hills Pharma, LLC
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #4729
  6. 2024
    Entered Top 25% Nationally
    Ranked #4729
  7. 2024
    Multi-Institutional Research
    Awards at 3 institutions